
    
      Arm A: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a week i.v followed by 48 weeks of
      treatment with 3 x 10 MIU/m2 s.c Arm B: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a
      week i.v repeated 3 times with 12 treatment-free-weeks between the cycles

      Secondary endpoints: Improved overall survival rate, Assess side effects of therapy in both
      treatment arms, Assess time spent on sick leave, Assess number of treatment-related days in
      hospital, Assess overall performance status, Assess blood MX protein levels
    
  